Final analysis of phase II results with cemiplimab in metastatic basal cell carcinoma after hedgehog pathway inhibitors

CONCLUSIONS: Cemiplimab demonstrated clinically meaningful antitumour activity, including durable responses, and an acceptable safety profile in patients with mBCC who had disease progression on or intolerance to HHI therapy.PMID:38072158 | DOI:10.1016/j.annonc.2023.10.123

Source: Ann Oncol - December 10, 2023 Category: Cancer & Oncology Authors: K D Lewis K Peris A Sekulic A J Stratigos L Dunn Z Eroglu A L S Chang M R Migden S-Y Yoo K Mohan E Coates E Okoye T Bowler J-F Baurain O Bechter A Hauschild M O Butler L Hernandez-Aya L Licitra R I Neves E S Ruiz F Seebach I Lowy P Goncalves M G Fury Source Type: research